In short
Clinical trials are investigating Ropeginterferon Alfa-2B in blood cancers and related blood disorders. These studies look at how well it works, how safe it is, and whether it improves disease control in adults with essential thrombocythaemia or chronic myeloid leukemia.
Key points
- Clinical trials of Ropeginterferon Alfa-2B are studying blood diseases, mainly essential thrombocythaemia and chronic myeloid leukemia. One trial is Phase 3 and one is Phase 2, so the research includes both larger confirmation studies and earlier testing. The essential thrombocythaemia study looks at patients who cannot use, do not respond to, or are not eligible for other cytoreductive treatments. The chronic myeloid leukemia study tests Ropeginterferon Alfa-2B together with bosutinib from diagnosis. The main outcomes include disease response, blood count control, molecular response, and whether the disease stays stable without progression.
Clinical trials overview
These studies are interventional trials, which means researchers give a treatment and then measure the results. They are studying Ropeginterferon Alfa-2B in two different blood diseases: essential thrombocythaemia and chronic myeloid leukemia.
Both trials are listed as Authorised and are being done in adults with specific disease settings. The main question in each study is whether Ropeginterferon Alfa-2B improves disease control and is safe enough for the target group.
Essential thrombocythaemia trial
The Phase 3 study in essential thrombocythaemia is a multicenter trial, meaning it is run at more than one study site. It plans to enroll 132 people.
This study is designed to estimate disease response rates according to modified ELN criteria, which are rules used to define how well the disease is controlled. The trial focuses on patients who are intolerant to, refractory to, or not eligible for other cytoreductive treatments.
The trial title and summary show that the study is looking at efficacy and safety of Ropeginterferon Alfa-2B in this patient group.
Chronic myeloid leukemia trial
The Phase 2 BosuPeg trial studies Ropeginterferon Alfa-2B in chronic myeloid leukemia patients who are treated with bosutinib from diagnosis. It plans to enroll 164 people.
This study is randomized and prospective, which means people are assigned to treatment groups by chance and then followed forward in time. The study compares bosutinib alone with bosutinib plus Ropeginterferon Alfa-2B.
The goal is to see whether adding Ropeginterferon Alfa-2B improves deep molecular response and may help more patients reach treatment-free remission.
What the trials measure
In the essential thrombocythaemia study, the main outcome is the rate of disease response at month 12 using modified ELN criteria. This includes durable blood count remission, no hemorrhagic or thrombotic events, no disease progression, no worsening of disease-related signs, and lasting improvement or stability in symptoms measured by the MPN-SAF TSS.
In simple terms, the study asks whether blood counts improve, symptoms stay controlled, and serious disease problems do not appear.
In the chronic myeloid leukemia study, the main outcome is the rate of molecular response 4 at 12 months in each treatment arm. A molecular response is a very deep response measured by disease markers in the blood.
This trial also looks at whether the combination treatment can increase the chance of treatment-free remission.
Who may take part
The essential thrombocythaemia trial is for patients who are intolerant to, refractory to, or not eligible for other cytoreductive treatments. These terms mean that previous treatment did not work well, caused problems, or was not suitable for the patient.
The chronic myeloid leukemia trial is for patients treated with bosutinib from diagnosis. The trial does not give more details in the source data about other eligibility rules.
Trial design and phases
The essential thrombocythaemia study is Phase 3, which usually means a larger study that helps confirm treatment benefit in a broader group of patients. The chronic myeloid leukemia study is Phase 2, which usually looks for early signs of benefit and continues to assess safety.
Both studies are interventional, so the treatment is actively given and then measured against study goals. Together, these trials show that Ropeginterferon Alfa-2B is being studied in different blood cancers with different treatment strategies and outcome measures.